Biogen: collaboration agreement with Sage Therapeutics
(CercleFinance.com) - Biogen announces a collaboration agreement with Sage Therapeutics to jointly develop and commercialize zuranolone in the US for major depressive disorders, postpartum depression and other psychiatric disorders.
The agreement also covers SAGE-324 in chronic shaking and other neurological disorders in the United States. Biogen will also receive an exclusive license for zuranolone and SAGE-324 outside the US, with the exception of rights in Japan, Taiwan and South Korea.
Sage Therapeutics will receive 1,525 million dollars in cash, including an upfront payment of 875 million dollars and 650 million dollars in capex, as well as potential milestone, profit-sharing and royalty payments.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The agreement also covers SAGE-324 in chronic shaking and other neurological disorders in the United States. Biogen will also receive an exclusive license for zuranolone and SAGE-324 outside the US, with the exception of rights in Japan, Taiwan and South Korea.
Sage Therapeutics will receive 1,525 million dollars in cash, including an upfront payment of 875 million dollars and 650 million dollars in capex, as well as potential milestone, profit-sharing and royalty payments.
Copyright (c) 2020 CercleFinance.com. All rights reserved.